6533b831fe1ef96bd1299a73

RESEARCH PRODUCT

The sphingosine kinase 1 activator, K6PC-5, attenuates Ebola virus infection

M. Javad AmanNerea FerreirósDagmar Meyer Zu HeringdorfFatah KashanchiJosef PfeilschifterSandra TrautmannGergely ImreKrishnaraj RajalingamMadeleine EichlerStefan PöhlmannVerena KrählingStephan Becker

subject

0301 basic medicineScienceviruses02 engineering and technologymedicine.disease_causeArticle03 medical and health scienceschemistry.chemical_compoundViral entryVirologymedicinechemistry.chemical_classificationMultidisciplinaryEbola virusSphingosinebiologyActivator (genetics)QMolecular MicrobiologyCell Biology021001 nanoscience & nanotechnologyVirologySphingolipid030104 developmental biologychemistrySphingosine kinase 1Cell culturebiology.protein0210 nano-technologyGlycoprotein

description

Summary Ebola virus (EBOV) is responsible for outbreaks with case fatality rates of up to 90% and for an epidemic in West Africa with more than ten thousand deaths. EBOV glycoprotein (EBOV-GP) is the only viral surface protein and is responsible for viral entry into cells. Here, by employing pseudotyped EBOV-GP viral particles, we uncover a critical role for sphingolipids in inhibiting viral entry. Sphingosine kinase 1 (SphK1) catalyzes the phosphorylation of sphingosine to sphingosine 1-phosphate (S1P). The administration of the SphK1 activator, K6PC-5, or S1P, or the overexpression of SphK1 consistently exhibited striking inhibitory effects in EBOV-GP-driven entry in diverse cell lines. Finally, K6PC-5 markedly reduced the EBOV titer in infected cells and the de novo production of viral proteins. These data present K6PC-5 as an efficient tool to inhibit EBOV infection in endothelial cells and suggest further studies to evaluate its systemic effects.

10.1016/j.isci.2021.102266http://europepmc.org/articles/PMC8005759